Literature DB >> 19478684

Nuclear PTEN levels and G2 progression in melanoma cells.

Abraham I Jacob1, Todd Romigh, Kristin A Waite, Charis Eng.   

Abstract

The phosphatase and tensin homolog (PTEN) exerts its function, in part, by negatively regulating the well-known phosphatidylinositol-3-kinase/AKT signaling pathway. Previous histological work has suggested that alterations in the nuclear/cytoplasmic compartmentalization of PTEN may play a role in the development and progression of melanoma. In this study, we examined the nuclear/cytoplasmic compartmentalization of PTEN in melanoma cell lines and its correlation with the cell cycle. Studies were performed in melanoma cells lines using classic cell biological techniques. In contrast to breast cancer cell lines, we found that increased levels of nuclear PTEN levels correlate with G2 rather than with G1 arrest. In WM164 and SKmel28 cells, overexpression of PTEN protein did not significantly increase the number of cells in the G2 phase. Differential CDC2 phosphorylation levels in cells that overexpressed PTEN compared with those where PTEN was downregulated suggest some involvement of PTEN in G2 checkpoint regulation. The data suggest that although nuclear PTEN levels correlate with the G2 phase, the role of PTEN in modulating G2/M arrest is not limiting. Further, the specific cell cycle phase regulated by nuclear PTEN is cell-type dependent. Taken together, our observations suggest that in melanoma, nuclear PTEN is involved in G2 progression possibly through the modulation of CDC2, opening up a new arena for investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478684      PMCID: PMC2750820          DOI: 10.1097/CMR.0b013e32832ccd6e

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  45 in total

1.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

Authors:  D J Marsh; P L Dahia; Z Zheng; D Liaw; R Parsons; R J Gorlin; C Eng
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

Review 2.  Cyclins and cyclin-dependent kinases: a biochemical view.

Authors:  J Pines
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

3.  Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.

Authors:  X P Zhou; D J Marsh; H Hampel; J B Mulliken; O Gimm; C Eng
Journal:  Hum Mol Genet       Date:  2000-03-22       Impact factor: 6.150

4.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 5.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.

Authors:  I U Ali; L M Schriml; M Dean
Journal:  J Natl Cancer Inst       Date:  1999-11-17       Impact factor: 13.506

6.  Estradiol and progesterone receptors in human cutaneous melanoma.

Authors:  A Stoica; M Hoffman; L Marta; N Voiculetz
Journal:  Neoplasma       Date:  1991       Impact factor: 2.575

7.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

8.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Authors:  D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

9.  PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.

Authors:  F Kimura; J Watanabe; H Hata; T Fujisawa; Y Kamata; Y Nishimura; T Jobo; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-20       Impact factor: 4.553

10.  Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors.

Authors:  O Gimm; A Perren; L P Weng; D J Marsh; J J Yeh; U Ziebold; E Gil; R Hinze; L Delbridge; J A Lees; G L Mutter; B G Robinson; P Komminoth; H Dralle; C Eng
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

View more
  10 in total

1.  PTEN inhibits proliferation and functions of hypertrophic scar fibroblasts.

Authors:  Liang Guo; Liang Chen; Sheng Bi; Linlin Chai; Zengxiang Wang; Chuan Cao; Ling Tao; Shirong Li
Journal:  Mol Cell Biochem       Date:  2011-10-12       Impact factor: 3.396

Review 2.  PTEN level in tumor suppression: how much is too little?

Authors:  Arkaitz Carracedo; Andrea Alimonti; Pier Paolo Pandolfi
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

3.  Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma.

Authors:  Suyun Wang; Zhiyong Cheng; Xiaoyang Yang; Kai Deng; Yan Cao; Hao Chen; Ling Pan
Journal:  Int J Hematol       Date:  2010-06-26       Impact factor: 2.490

4.  ΔNp63α represses nuclear translocation of PTEN by inhibition of NEDD4-1 in keratinocytes.

Authors:  Mary K Leonard; Natasha T Hill; Ethan D Grant; Madhavi P Kadakia
Journal:  Arch Dermatol Res       Date:  2013-04-16       Impact factor: 3.017

5.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

6.  PTEN Physically Interacts with and Regulates E2F1-mediated Transcription in Lung Cancer.

Authors:  Prerna Malaney; Emily Palumbo; Jonathan Semidey-Hurtado; Jamaal Hardee; Katherine Stanford; Jaymin J Kathiriya; Deepal Patel; Zhi Tian; Diane Allen-Gipson; Vrushank Davé
Journal:  Cell Cycle       Date:  2018-05-31       Impact factor: 4.534

7.  Nongenomic Mechanisms of PTEN Regulation.

Authors:  Jimmie E Fata; Shawon Debnath; Edmund C Jenkins; Marcia V Fournier
Journal:  Int J Cell Biol       Date:  2012-03-25

Review 8.  Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.

Authors:  Akari Minami; Atsuko Nakanishi; Yasunori Ogura; Yasuko Kitagishi; Satoru Matsuda
Journal:  Front Oncol       Date:  2014-11-10       Impact factor: 6.244

9.  PTEN inhibits BMI1 function independently of its phosphatase activity.

Authors:  Catherine Fan; Lizhi He; Anil Kapoor; Adrian P Rybak; Jason De Melo; Jean-Claude Cutz; Damu Tang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

10.  Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development.

Authors:  Magdalena Mizerska-Kowalska; Agnieszka Bojarska-Junak; Joanna Jakubowicz-Gil; Martyna Kandefer-Szerszeń
Journal:  Tumour Biol       Date:  2016-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.